Trial Profile
Prospective multicenter study regarding the efficacy of Gemcitabine (gemzar) plus nab-Paclitaxel (Abraxane) regimen for locally advanced pancreatic cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2022
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms GEAR study
- 01 Jan 2023 Results published in the Annals of Surgical Oncology
- 18 Dec 2021 Status changed from active, no longer recruiting to completed.
- 17 Jun 2020 Status changed from recruiting to active, no longer recruiting.